[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053600":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":57,"centralContacts":61,"locations":68,"responsibleParty":154,"collaborators":66,"id":156,"slug":157,"hasResults":158,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":66,"eligibilityCriteria":162,"healthyVolunteers":158,"sex":163,"minAge":164,"maxAge":66,"enrollmentInfo":165,"targetDuration":66,"studyType":168,"phases":169,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":71,"whyStopped":66,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MK-8294","EXPERIMENTAL","Participants will receive MK-8294 monotherapy in escalating doses starting from 30 µg up to a planned 70 mg via intravenous (IV) infusion. In addition, intermediate doses may also be assessed. MK-8294 will be administered on Day 1, Day 8, and Day 15 of each cycle (each cycle = 21 days). Per protocol treatment of MK-8294 has no maximum number of cycles. Participants will be treated until any of the criteria for discontinuation of study intervention are met. Participants may also receive a cluster of differentiation 8 (CD8) positron emission tomography (PET) tracer as a part of optional PET imaging.",[13,14],"Drug: MK-8294","Other: CD8 PET Tracer",[16,22,26,30,34,38,42,46,50],{"type":17,"name":9,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","30 µg via intravenous (IV) infusion",[9],[21],"DAB014236",{"type":17,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"100 µg via intravenous (IV) infusion",[9],[21],{"type":17,"name":9,"description":27,"armGroupLabels":28,"otherNames":29},"300 µg via intravenous (IV) infusion",[9],[21],{"type":17,"name":9,"description":31,"armGroupLabels":32,"otherNames":33},"1 mg via intravenous (IV) infusion",[9],[21],{"type":17,"name":9,"description":35,"armGroupLabels":36,"otherNames":37},"3 mg via intravenous (IV) infusion",[9],[21],{"type":17,"name":9,"description":39,"armGroupLabels":40,"otherNames":41},"10 mg via intravenous (IV) infusion",[9],[21],{"type":17,"name":9,"description":43,"armGroupLabels":44,"otherNames":45},"30 mg via intravenous (IV) infusion",[9],[21],{"type":17,"name":9,"description":47,"armGroupLabels":48,"otherNames":49},"70 mg via intravenous (IV) infusion",[9],[21],{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":55},"OTHER","CD8 PET Tracer","IV Infusion",[9],[56],"GEH200520 + GEH200521 (18F)",[58],{"name":59,"affiliation":5,"role":60},"Medical Director","STUDY_DIRECTOR",[62],{"name":63,"role":64,"phone":65,"phoneExt":66,"email":67},"Toll Free Number","CONTACT","1-888-577-8839",null,"Trialsites@msd.com",[69,87,100,114,126,141],{"facility":70,"status":71,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"Northwestern University ( Site 0101)","RECRUITING","Chicago","Illinois","60611","United States","US",{"type":78,"coordinates":79},"Point",[80,81],-87.65005,41.85003,{"lat":81,"lon":80},[84],{"name":85,"role":64,"phone":86,"phoneExt":66,"email":66},"Study Coordinator","312-926-8105",{"facility":88,"status":71,"city":89,"state":90,"zip":91,"country":75,"countryCode":76,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Houston Methodist Hospital ( Site 0103)","Houston","Texas","77030",{"type":78,"coordinates":93},[94,95],-95.36327,29.76328,{"lat":95,"lon":94},[98],{"name":85,"role":64,"phone":99,"phoneExt":66,"email":66},"346-238-4516",{"facility":101,"status":71,"city":102,"state":66,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Rambam Health Care Campus ( Site 0201)","Haifa","3109601","Israel","IL",{"type":78,"coordinates":107},[108,109],34.99928,32.81303,{"lat":109,"lon":108},[112],{"name":85,"role":64,"phone":113,"phoneExt":66,"email":66},"972(47776234)",{"facility":115,"status":71,"city":116,"state":66,"zip":117,"country":104,"countryCode":105,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Sheba Medical Center ( Site 0200)","Ramat Gan","5265601",{"type":78,"coordinates":119},[120,121],34.81065,32.08227,{"lat":121,"lon":120},[124],{"name":85,"role":64,"phone":125,"phoneExt":66,"email":66},"972(35307039)",{"facility":127,"status":71,"city":128,"state":129,"zip":130,"country":131,"countryCode":132,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Radboudumc ( Site 0301)","Nijmegen","Gelderland","6525 GA","Netherlands","NL",{"type":78,"coordinates":134},[135,136],5.85278,51.8425,{"lat":136,"lon":135},[139],{"name":85,"role":64,"phone":140,"phoneExt":66,"email":66},"0243611111",{"facility":142,"status":71,"city":143,"state":144,"zip":145,"country":131,"countryCode":132,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0300)","Amsterdam","North Holland","1066 CX",{"type":78,"coordinates":147},[148,149],4.88969,52.37403,{"lat":149,"lon":148},[152],{"name":85,"role":64,"phone":153,"phoneExt":66,"email":66},"+31205129111",{"type":155,"investigatorFullName":66,"investigatorTitle":66,"investigatorAffiliation":66,"oldNameTitle":66,"oldOrganization":66},"SPONSOR","100053600","phase-1-a-clinical-study-of-mk-8294-in-participants-with-advanced-solid-tumors-mk-8294-001-100053600",false,"NCT07030712","A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)","A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-8294 Monotherapy in Advanced Solid Tumors","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has histologically or cytologically confirmed advanced\u002Fmetastatic solid tumor; including head and neck squamous cell carcinoma, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, breast cancer (triple negative breast cancer, Estrogen Receptor \\[ER\\]\u002Fprogesterone receptor +, human epidermal growth factor receptor 2 negative \\[HER2-\\]), endometrial, and bladder cancer by pathology report and have previously failed standard treatment, lack standard treatment options, or are intolerant to standard treatment\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has a history of New York Heart Association Class II or greater heart failure\n* Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related Adverse Event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis\n* Has ongoing radiation-related toxicities, requiring corticosteroids\n* Has known additional malignancy that is progressing or has required active treatment within the past 2 years\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid)\n* Has active infection requiring systemic therapy\n* Has history of stem cell\u002Fsolid organ transplant\n* Has not adequately recovered from major surgery or have ongoing surgical complications","ALL","18 Years",{"count":166,"type":167},67,"ESTIMATED","INTERVENTIONAL",[170],"PHASE1","MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.",[173],"Metastatic Neoplasm",[175,176],"Metastases","Neoplasm","2026-07-10",{"date":179,"type":180},"2026-07-13","ACTUAL",{"date":182,"type":180},"2025-07-23",{"date":184,"type":167},"2027-08-23",{"name":5,"class":6},6]